The FDA had required Novo Nordisk to modify its FDA-mandated risk evaluation and mitigation strategies. Read more
Novo Nordisk, Inc. will pay $25 million to settle a whistleblower lawsuit that involved the illegal off-label marketing of hemostasis management drug, NovoSeven. Once approved by the FDA, a... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.